Evidence map›Paper›PMID 31361167›Full record

ReviewImmunotherapy2019

Recent advances with Treg depleting fusion protein toxins for cancer immunotherapy.

Pankaj Kumar, Amit Kumar, Sadiya Parveen, John R Murphy, William Bishai

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Bacteria-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Pankaj KumarDepartment of Medicine, Johns Hopkins School of Medicine, 1550 Orleans Street, Baltimore, MD 21287, USA.
Amit KumarDepartment of Medicine, Johns Hopkins School of Medicine, 1550 Orleans Street, Baltimore, MD 21287, USA.
Sadiya ParveenDepartment of Medicine, Johns Hopkins School of Medicine, 1550 Orleans Street, Baltimore, MD 21287, USA.
John R MurphyDepartment of Medicine, Johns Hopkins School of Medicine, 1550 Orleans Street, Baltimore, MD 21287, USA.
William BishaiDepartment of Medicine, Johns Hopkins School of Medicine, 1550 Orleans Street, Baltimore, MD 21287, USA.
Johns Hopkins University · USJohns Hopkins Medicine · US

Funding

Targeted Immunotherapy for Tuberculosis and HIV co-infectionR21AI130595 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BISHAI, WILLIAM RAMSES · 2017 to 2018
$449k
NIAID NIH HHS R21 AI130595
6 · The paper itself

Abstract

T regulatory cells (Tregs) are an important T cell population for immune tolerance, prevention of autoimmune diseases and inhibition of antitumor immunity. The tumor-promoting role played by Tregs in cancer has prompted numerous approaches to develop immunotherapeutics targeting Tregs. One approach to depletion of Treg cells is retargeting the highly potent cytotoxic activity of bacterial toxins. These agents capitalize on the well-characterized bacterial toxins, diphtheria toxin and

Indexed as

ADP Ribose TransferasesAnimalsBacterial ToxinsClinical Trials as TopicDiphtheria ToxinDrug Evaluation, PreclinicalExotoxinsHumansImmunity, CellularImmunotherapyLymphocyte DepletionNeoplasmsPseudomonas aeruginosa Exotoxin AT-Lymphocytes, RegulatoryTumor MicroenvironmentVirulence FactorsADP Ribose TransferasesBacterial ToxinsDiphtheria ToxinExotoxinsPseudomonas aeruginosa Exotoxin AVirulence Factorsanticancer therapydenileukin diftitoxfusion protein toxinsimmunotherapyLMB-2melanomatargeted toxinsTregs

Identifiers

PMID31361167
PMCPMC7006781
OpenAlexW2964805835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.